
GRDN Stock Forecast & Price Target
GRDN Analyst Ratings
Bulls say
Guardian Pharmacy Service is poised for growth due to several key factors. Its strong financial flexibility and robust technology assets set it apart from competitors in the fragmented long-term care pharmacy industry, positioning the company as a leader. In addition, the company's expansion activity and recent acquisitions are driving significant earnings opportunities and their local leadership model allows for improved customer service. We remain bullish on Guardian, reiterated our Buy rating and raised our price target to $38 to reflect the company's strong 4Q results, positive outlook for FY2026, and potential for future growth and share gain opportunities.
Bears say
Guardian Pharmacy Service is a pharmacy services company that faces potential regulatory and investigational risks due to its operations being highly regulated. The company also has a limited trading liquidity and faces exposure to reimbursement mechanisms between PBMs and drug manufacturers, which could impact its financial performance. While the company has a strong cash flow and financial flexibility, there remain concerns about its ability to turn around acquired assets and mitigate the earnings impact of drug price negotiations related to IRA.
This aggregate rating is based on analysts' research of Guardian Pharmacy Services Inc and is not a guaranteed prediction by Public.com or investment advice.
GRDN Analyst Forecast & Price Prediction
Start investing in GRDN
Order type
Buy in
Order amount
Est. shares
0 shares